{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:51:20Z","timestamp":1779223880251,"version":"3.51.4"},"reference-count":29,"publisher":"China Science Publishing & Media Ltd.","issue":"1","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770567"],"award-info":[{"award-number":["81770567"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.1093\/abbs\/gmaa143","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T12:17:38Z","timestamp":1604924258000},"page":"29-35","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["Combined chemotherapy of platinum and fluorouracil promotes T cell–mediated antitumor immunity"],"prefix":"10.3724","volume":"53","author":[{"given":"Yixiao","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2026","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"null","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"Ajani JA","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol, 2010, 28: 1547-1553.","journal-title":"J Clin Oncol"},{"key":"null","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1182\/blood-2012-06-436568","volume":"121","author":"Schmidt K","year":"2013","unstructured":"Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willimsky G. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood, 2013, 121: 1740-1748.","journal-title":"Blood"},{"key":"null","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"De Visser KE","year":"2006","unstructured":"De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer, 2006, 6: 24-37.","journal-title":"Nat Rev Cancer"},{"key":"null","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-009-0161-8","volume":"31","author":"Waldner MJ","year":"2009","unstructured":"Waldner MJ, Neurath MF. Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol, 2009, 31:","journal-title":"Semin Immunopathol"},{"key":"null","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.11.6047","volume":"165","author":"Marzo AL","year":"2000","unstructured":"Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B. Tumor-specific CD4+ T cells have a major \u201cpost-licensing\u201d role in CTL mediated anti-immunity. J Immunol, 2000, 165:","journal-title":"J Immunol"},{"key":"null","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1158\/0008-5472.CAN-17-2426","volume":"78","author":"Haabeth OAW","year":"2018","unstructured":"Haabeth OAW, Fauskanger M, Manzke M, Lundin KU, Corthay A, Bogen B, Tveita AA. CD4+ T-cell\u2013mediated rejection of MHC class II\u2013positive tumor cells is dependent on antigen secretion and indirect presentation on host APCs. Cancer Res, 2018, 78: 4573-4585.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","volume":"27","author":"Smith-Garvin JE","year":"2009","unstructured":"Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol, 2009, 27: 591-619.","journal-title":"Annu Rev Immunol"},{"key":"null","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","volume":"28","author":"Zhu J","year":"2010","unstructured":"Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol, 2010, 28: 445-489.","journal-title":"Annu Rev Immunol"},{"key":"null","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","volume":"222","author":"Kennedy R","year":"2008","unstructured":"Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev, 2008, 222: 129-144.","journal-title":"Immunol Rev"},{"key":"null","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1084\/jem.189.5.803","volume":"189","author":"Schuler T","year":"1999","unstructured":"Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med, 1999, 189: 803-810.","journal-title":"J Exp Med"},{"key":"null","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1084\/jem.190.5.617","volume":"190","author":"Nishimura T","year":"1999","unstructured":"Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med, 1999, 190: 617-627.","journal-title":"J Exp Med"},{"key":"null","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nm.2856","volume":"18","author":"Purwar R","year":"2012","unstructured":"Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM. Robust tumor immunity to melanoma mediated by interleukin-9\u2013producing T cells. Nat Med, 2012, 18: 1248-1253.","journal-title":"Nat Med"},{"key":"null","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4049\/jimmunol.1001183","volume":"186","author":"Eller K","year":"2011","unstructured":"Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie ANJ, Maurer M. IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol, 2011, 186: 83-91.","journal-title":"J Immunol"},{"key":"null","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00005-008-0018-1","volume":"56","author":"Kosmaczewska A","year":"2008","unstructured":"Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz), 2008, 56: 181-191.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"null","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03530-3","volume":"9","author":"Liu J","year":"2018","unstructured":"Liu J, Huang XF, Hao SM, Wang Y, Liu MM, Xu J, Zhang X. Peli1 negatively regulates noncanonical NF-\u03baB signalling to restrain systemic lupus erythematosus. Nat Commun, 2018, 9:","journal-title":"Nat Commun"},{"key":"null","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1586\/era.09.149","volume":"9","author":"Ryu MH","year":"2009","unstructured":"Ryu MH, Kang YK. ML17032 trial: capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in advanced gastric cancer. Expert Rev Anticancer Ther, 2009, 9: 1745-1751.","journal-title":"Expert Rev Anticancer Ther"},{"key":"null","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"Bang YJ","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, 2012, 379: 315-321.","journal-title":"Lancet"},{"key":"null","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tox.2003.08.011","volume":"195","author":"Lee R","year":"2004","unstructured":"Lee R, Kim YJ, Lee YJ, Chung HW. The selective effect of genistein on the toxicity of bleomycin in normal lymphocytes and HL-60 cells. Toxicology, 2004, 195: 87-95.","journal-title":"Toxicology"},{"key":"null","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/CJI.0b013e3181ea7e6e","volume":"33","author":"Laurent J","year":"2010","unstructured":"Laurent J, Speiser DE, Appay V, Touvrey C, Vicari M, Papaioannou A, Canellini G. Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. J Immunother, 2010, 33: 723-734.","journal-title":"J Immunother"},{"key":"null","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.20021683","volume":"197","author":"Mattes J","year":"2003","unstructured":"Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, Parish C. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med, 2003, 197: 387-393.","journal-title":"J Exp Med"},{"key":"null","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1074-7613(00)80218-6","volume":"12","author":"Qin Z","year":"2000","unstructured":"Qin Z, Blankenstein T. CD4+ T cell\u2013mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN\u03b3 receptor expression by nonhematopoietic cells. Immunity, 2000, 12: 677-686.","journal-title":"Immunity"},{"key":"null","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/nm.3922","volume":"21","author":"Kim IK","year":"2015","unstructured":"Kim IK, Kim BS, Koh CH, Seok JW, Park JS, Shin KS, Bae EA. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9\u2013producing helper T cells. Nat Med, 2015, 21: 1010-1017.","journal-title":"Nat Med"},{"key":"null","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms9266","volume":"6","author":"Xiao X","year":"2015","unstructured":"Xiao X, Shi X, Fan Y, Zhang X, Wu M, Lan P, Minze L. GITR subverts Foxp3+ Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun, 2015, 6: 1-13.","journal-title":"Nat Commun"},{"key":"null","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.4049\/jimmunol.168.7.3484","volume":"168","author":"Seki N","year":"2002","unstructured":"Seki N, Brooks AD, Carter CRD, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol, 2002, 168: 3484-3492.","journal-title":"J Immunol"},{"key":"null","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/j.1349-7006.2011.01962.x","volume":"102","author":"Kano M","year":"2011","unstructured":"Kano M, Tsukahara T, Emori M, Murase M, Torigoe T, Kawaguchi S, Wada T. Autologous CTL response against cancer stem-like cells\/cancer-initiating cells of bone malignant fibrous histiocytoma. Cancer Sci, 2011, 102: 1443-1447.","journal-title":"Cancer Sci"},{"key":"null","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1172\/JCI27745","volume":"116","author":"Quezada SA","year":"2006","unstructured":"Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest, 2006, 116: 1935-1945.","journal-title":"J Clin Invest"},{"key":"null","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","volume":"72","author":"Sisirak V","year":"2012","unstructured":"Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S. Impaired IFN-\u03b1 production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res, 2012, 72: 5188-5197.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"Kelland L","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 2007, 7: 573-584.","journal-title":"Nat Rev Cancer"},{"key":"null","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"Andr\u00e9 T","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 2004, 350: 2343-2351.","journal-title":"N Engl J Med"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/84A2D028FE3741FA99782DDABF3E4B7E","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmaa143","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/abbs\/advance-article-pdf\/doi\/10.1093\/abbs\/gmaa143\/34357752\/gmaa143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/84A2D028FE3741FA99782DDABF3E4B7E","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:26:13Z","timestamp":1659003973000},"score":1,"resource":{"primary":{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmaa143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,17]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abbs\/gmaa143","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}